Report cover image

Global Targeted Drugs for Multiple Myeloma Market Growth (Status and Outlook) 2025-2031

Publisher LP Information, Inc.
Published Sep 10, 2025
Length 172 Pages
SKU # LPI20388118

Description

According to this study, the global Targeted Drugs for Multiple Myeloma market size will reach US$ million by 2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “Targeted Drugs for Multiple Myeloma Industry Forecast” looks at past sales and reviews total world Targeted Drugs for Multiple Myeloma sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Drugs for Multiple Myeloma sales for 2025 through 2031. With Targeted Drugs for Multiple Myeloma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Drugs for Multiple Myeloma industry.

This Insight Report provides a comprehensive analysis of the global Targeted Drugs for Multiple Myeloma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drugs for Multiple Myeloma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Drugs for Multiple Myeloma market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drugs for Multiple Myeloma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drugs for Multiple Myeloma.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drugs for Multiple Myeloma market by product type, application, key players and key regions and countries.

Segmentation by Type:
Immunomodulator
Proteasome Inhibitors
Histone Deacetylase Inhibitors (HDACI)
Monoclonal Antibody
Others

Segmentation by Application:
Hospital
Drug Center
Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Celgene
Exova
Natco Pharma
Intas Pharmaceuticals
Indiabulls Pharmaceutical
Cipla
Glenmark Pharmaceuticals
Dr Reddy's Laboratories
Qilu Pharmaceutical
Chia Tai-Tianqing
Hanson Pharm
Meidakang Huakang Pharmaceutical
Shandong Kongfu Pharmaceutical
J&J
Takeda
Amgen
Bristol Myers Squibb
Abbvie
Seattle Genetics
Karyopharm Therapeutics
PDL BioPharma
Roche
Sumitomo
Merck
Biogen
Schering-Plough
Glaxo
Chiron

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

172 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
2 Executive Summary
3 Targeted Drugs for Multiple Myeloma Market Size by Player
4 Targeted Drugs for Multiple Myeloma by Region
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Global Targeted Drugs for Multiple Myeloma Market Forecast
11 Key Players Analysis
12 Research Findings and Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us